

## WHAT IS CLAIMED IS:

- 5
1. A method for the prevention of constrictive remodeling comprising the controlled delivery, by release from an intraluminal medical device, of a compound in therapeutic dosage amounts.
- 10
2. The method for the prevention of constrictive remodeling according to Claim 1, further includes utilizing the compound to block the proliferation of fibroblasts in the vascular wall in response to injury, thereby reducing the formation of vascular scar tissue.
- 15
3. The method for the prevention of constrictive remodeling according to Claim 2, wherein the compound comprises rapamycin.
- 20
4. The method for the prevention of constrictive remodeling according to Claim 2, wherein the compound comprises analogs and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses the same pharmacologic properties as rapamycin.
- 25
5. The method for the prevention of constrictive remodeling according to Claim 1, further includes utilizing the compound to affect the translation of certain proteins involved in the collagen formation or metabolism.
- 30
6. The method for the prevention of constrictive remodeling according to Claim 5, wherein the compound comprises rapamycin.
7. The method for the prevention of constrictive remodeling according to Claim 5, wherein the compound comprises analogs and congeners that bind a high-affinity cytosolic protein, FKBP12, and possesses the same pharmacologic properties as rapamycin.

8. A drug delivery device comprising:  
an intraluminal medical device; and  
a therapeutic dosage of an agent releasably affixed to the  
intraluminal medical device for the treatment of constrictive vascular  
remodeling.

9. The drug delivery device according to Claim 8, wherein the agent  
blocks the proliferation of fibroblasts in the vascular wall in response to  
injury, thereby reducing the formation of vascular scar tissue.

10. ~~The drug delivery device according to Claim 9, wherein the agent  
comprises rapamycin.~~

11. The drug delivery device according to Claim 9, wherein the agent  
comprises analogs and congeners that bind a high-affinity cytosolic  
protein, FKBP12, and possesses the same pharmacologic properties as  
rapamycin.

12. The drug delivery device according to Claim 8, wherein the agent  
affects the translation of certain proteins involved in the collagen  
formation or metabolism.

13. ~~The drug delivery device according to Claim 12, wherein the  
agent comprises rapamycin.~~

14. The drug delivery device according to Claim 12, wherein the  
agent comprises analogs and congeners that bind a high-affinity  
cytosolic protein, FKBP12, and possesses the same pharmacologic  
properties as rapamycin.

15. The drug delivery device according to Claim 8, wherein the  
intraluminal medical device comprises a stent.